Real-World Clinical Experience With Idebenone in the Treatment of Leber Hereditary Optic Neuropathy

Update Item Information
Title Real-World Clinical Experience With Idebenone in the Treatment of Leber Hereditary Optic Neuropathy
Creator Claudia B. Catarino, MD, PhD; Bettina von Livonius, MD; Claudia Priglinger, MD; Rudrani Banik, MD; Selma Matloob, MBChB, MRCOphth; Madhura A. Tamhankar, MD; Lorena Castillo, MD; Christoph Friedburg, MD, FEBO; Christopher A. Halfpenny, MBBS, PhD; John A. Lincoln, MD, PhD; Ghislaine L. Traber, MD; Gölge Acaroglu, MD; Graeme C. M. Black, DPhil, FRCOphth; Carlos Doncel, MD; Clare L. Fraser, MBBS, MMed; Joanna Jakubaszko, MD, PhD; Klara Landau, MD, FEBO; Stefan J. Langenegger, MD, FEBO; Francisco J. Muñoz- Negrete, MD, PhD; Nancy J. Newman, MD; Joanna Poulton, DM, MRCPCH; Elisabetta Scoppettuolo, MBBS, FRCOphth; Prem Subramanian, MD, PhD; Ahmed T. Toosy, MBBS, FRCP; Mariona Vidal, MD; Andrea L. Vincent, MBChB, MD; Marcela Votruba, BM BCh, FRCOphth; Marcin Zarowski, MD, PhD; Adam Zermansky, MBChB, FRCP; Felice Lob, MD; Günther Rudolph, MD; Oskars Mikazans, MA; Magda Silva; Xavier Llòria, MD; Günther Metz, PhD; Thomas Klopstock; MD
Affiliation Department of Neurology (CBC, OM, TK), Friedrich-Baur-Institute, University Hospital of the Ludwig-Maximilians-University, Munich, Ger- many; German Center for Neurodegenerative Diseases (DZNE) (CBC, TK), Munich, Germany; Department of Ophthalmology (BL, CP, FL, GR), University Hospital of the Ludwig-Maximilians-University Munich, Germany; New York Eye and Ear Infirmary of Mount Sinai (RB), New York, New York; Ophthalmology Department (SM), Waikato Hospital, Hamilton, New Zealand; Scheie Eye Institute (MAT), University of Pennsylvania, Philadelphia, Pennsylvania; Institut Català de Retina (LC), Barcelona, Spain; Augenklinik (CF), Universitätsklinikum Giessen, Giessen, Germany; University Hospital Southampton (CAH), Southampton, United Kingdom; McGovern Medical School (JAL), UTHealth, Houston, Texas; Department of Ophthalmology (GLT, KL, SJL), University Hospital and University of Zurich, Zurich, Switzerland; Neuro-ophthalmology Associates (GA), Ankara, Turkey; Manchester Centre for Genomic Medicine (GCMB), Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, St Mary's Hospital, Manchester, United Kingdom; Division of Evolution and Genomic Sciences (GCMB), Neuroscience and Mental Health Domain, School of Health Sciences, Faculty of Biology, Medicines and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom; Ophthalmology Unit (CD), Hospital de Poniente, El Ejido, Almería, Spain; Save Sight Institute (CLF), University of Sydney, Sydney, Australia; Department of Pediatric Traumatology and Emergency Medicine (JJ), Wroclaw Medical University, Poland; Poland SPEKTRUM Ophthalmology Clinic (JJ), Wroclaw, Poland; University Hospital Ramon y Cajal (FJM-N), IRYCIS, Madrid, Spain; Emory University School of Medicine (NJN), Atlanta Georgia; Nuffield Dept Obstetrics and Gynaecology (JP), University of Oxford, The Women's Centre, Oxford, United Kingdom; Department of Ophthalmology (ES), East Kent Hospitals University Foundation Trust, United Kingdom; Neuro-Ophthalmology Division (PS), University of Colorado School of Medicine, Aurora, Colorado; Department of Neuroinflammation (ATT), Queen Square MS Centre, UCL Institute of Neurology, University College London, London, United Kingdom; Hospital Sant Joan de Déu Barcelona (MV), Barcelona, Spain; Eye Department (ALV), Greenlane Clinical Centre, Auckland, New Zealand; School of Optometry and Vision Sciences (MV), Cardiff University, Cardiff, United Kingdom; Department of Developmental Neurology (MZ), Poznan University of Medical Sciences, Poznan, Poland; Manchester Centre for Clinical Neuroscience (AZ), Salford Royal NHS Foundation Trust, Salford, United Kingdom; Neuro-ophthalmology Unit (MS, XL, GM) Santhera Pharmaceuticals, Pratteln, Switzerland; and Munich Cluster for Systems Neurology (SyNergy) (TK), Munich, Germany
Abstract Leber hereditary optic neuropathy (LHON) leads to bilateral central vision loss. In a clinical trial setting, idebenone has been shown to be safe and to provide a trend toward improved visual acuity, but long-term evidence of effectiveness in real-world clinical practice is sparse.
Subject Adolescent; Adult; Aged; Antioxidants, therapeutic use; Child; Female; Follow-Up Studies; Humans; Male; Middle Aged; Optic Atrophy, Hereditary, Leber / drug therapy; Optic Atrophy, Hereditary, Leber / physiopathology; Retrospective Studies; Time Factors; Treatment Outcome; Ubiquinone / analogs & derivatives*; Ubiquinone / therapeutic use; Visual Acuity; Young Adult
OCR Text Show
Date 2020-12
Language eng
Format application/pdf
Type Text
Publication Type Journal Article
Source Journal of Neuro-Ophthalmology, December 2020, Volume 40, Issue 4
Collection Neuro-Ophthalmology Virtual Education Library: Journal of Neuro-Ophthalmology Archives: https://novel.utah.edu/jno/
Publisher Lippincott, Williams & Wilkins
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management © North American Neuro-Ophthalmology Society
ARK ark:/87278/s64nvmsz
Setname ehsl_novel_jno
ID 1741123
Reference URL https://collections.lib.utah.edu/ark:/87278/s64nvmsz
Back to Search Results